Corcept Therapeutics financials
$114.74−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $256.1M | $164.9M | $202.1M | $207.6M | $194.4M | $157.2M | $181.9M | $182.5M | $163.8M | $146.8M | $135.4M | $123.6M |
| Gross profit | $252.1M | $162.0M | $199.6M | $203.0M | $191.0M | $154.8M | $178.9M | $179.7M | $161.3M | $144.3M | $133.5M | $122.0M |
| Gross margin | 98.4% | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% | 98.5% | 98.3% | 98.6% | 98.7% |
| Operating income | $41.3M | -$49.6M | $4.5M | $10.2M | $26.7M | $3.4M | $25.3M | $46.6M | $35.6M | $29.5M | $31.7M | $31.2M |
| Net income | $43.0M | -$31.8M | $23.9M | $19.4M | $35.1M | $20.5M | $30.4M | $46.7M | $35.1M | $27.8M | $31.1M | $31.2M |
| Net margin | 16.8% | −19.3% | 11.8% | 9.3% | 18.1% | 13.1% | 16.7% | 25.6% | 21.4% | 18.9% | 23.0% | 25.2% |
| Diluted EPS | $0.36 | $-0.30 | $0.20 | $0.16 | $0.29 | $0.17 | $0.26 | $0.41 | $0.32 | $0.25 | $0.28 | $0.28 |
| EBITDA | $42.2M | -$49.0M | $4.8M | $10.5M | $27.1M | $3.9M | $25.5M | $46.9M | $35.7M | $29.6M | $31.7M | $31.4M |
| Operating cash flow | $33.5M | -$16.8M | $38.4M | $54.5M | $44.3M | $4.8M | $60.1M | $73.3M | $41.2M | $23.8M | $5.9M | $52.9M |
| Free cash flow | $31.0M | -$17.0M | $38.4M | $54.5M | $44.2M | $4.7M | $59.9M | $71.7M | $40.8M | $23.8M | $5.9M | $52.9M |
| Diluted shares | 118.4M | 104.4M | 120.2M | 119.4M | 120.5M | 119.8M | 119.0M | 113.7M | 111.2M | 109.9M | 110.9M | 111.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $111.0M | $108.7M | $120.5M | $125.1M | $102.7M | $89.8M |
| Short-term investments | $197.2M | $229.4M | $251.7M | $296.5M | $239.5M | $232.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $888.7M | $814.9M | $836.7M | $823.6M | $801.7M | $846.5M |
| Total liabilities | $182.9M | $176.9M | $188.8M | $191.7M | $165.9M | $163.2M |
| Shareholders' equity | $705.8M | $638.0M | $647.8M | $631.9M | $635.8M | $683.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology